- Home
- GOCO vs GNLX Comparison
GOCO vs GNLX Comparison
Compare GOCO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOCO
- GNLX
- Stock Information
- Founded
- GOCO 2001
- GNLX 2001
- Country
- GOCO United States
- GNLX United States
- Employees
- GOCO N/A
- GNLX N/A
- Industry
- GOCO Specialty Insurers
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- GOCO Finance
- GNLX Health Care
- Exchange
- GOCO Nasdaq
- GNLX Nasdaq
- Market Cap
- GOCO 64.9M
- GNLX 110.9M
- IPO Year
- GOCO 2020
- GNLX 2023
- Fundamental
- Price
- GOCO $5.93
- GNLX $3.09
- Analyst Decision
- GOCO Hold
- GNLX Strong Buy
- Analyst Count
- GOCO 1
- GNLX 4
- Target Price
- GOCO $18.00
- GNLX $17.75
- AVG Volume (30 Days)
- GOCO 72.9K
- GNLX 137.5K
- Earning Date
- GOCO 08-07-2025
- GNLX 08-13-2025
- Dividend Yield
- GOCO N/A
- GNLX N/A
- EPS Growth
- GOCO N/A
- GNLX N/A
- EPS
- GOCO N/A
- GNLX N/A
- Revenue
- GOCO $834,266,000.00
- GNLX N/A
- Revenue This Year
- GOCO $8.51
- GNLX N/A
- Revenue Next Year
- GOCO $7.19
- GNLX N/A
- P/E Ratio
- GOCO N/A
- GNLX N/A
- Revenue Growth
- GOCO 13.18
- GNLX N/A
- 52 Week Low
- GOCO $5.01
- GNLX $1.60
- 52 Week High
- GOCO $21.00
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- GOCO 46.24
- GNLX 56.10
- Support Level
- GOCO $5.51
- GNLX $2.75
- Resistance Level
- GOCO $6.32
- GNLX $3.17
- Average True Range (ATR)
- GOCO 0.50
- GNLX 0.23
- MACD
- GOCO 0.14
- GNLX -0.00
- Stochastic Oscillator
- GOCO 42.26
- GNLX 56.94
About GOCO GoHealth Inc.
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.